CA-XSOLLA
Xsolla, a global video game commerce company, announced today that it has expanded their mobile and digital distribution solutions to provide more opportunities for developers to launch and grow their games around the world. In addition, Xsolla has added a new checkout feature to help developers scale their brands by selling and distributing NFTs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220428005554/en/
“Xsolla is committed to providing best-in-class services and support for developers worldwide to help them reach more players in more geographies,” stated Chris Hewish, President of Xsolla. “We continue to develop new features that target the key challenges of marketing, launching, and monetizing video games. We have more to come in 2022 that will keep our partners ahead of the constantly evolving game climate.”
Mobile Web Shop - New Features
As the expanding mobile landscape continues to lead global gaming revenue, Xsolla’s Web Shop for Mobile Games has added new features to help mobile developers to reach more players and to remain at the forefront of the mobile gaming revolution.
● Expanded Analytics
Developers can create a transparent funnel that will increase efficiency in bringing new players to their Web Shop. This will help developers understand the player experience online and determine where and how users engage with their game.
● Unique Promotions
This built-in component helps developers benefit from in-app purchases through their Web Shop. Within the online experience, developers can provide promotional offers and launch discount campaigns, promo code offers, and bonuses to boost sales and bring new players online.
● Subscriptions Management
To help developers sell a complete catalog of digital goods in their Web Shop, Xsolla added robust subscription features. This allows developers to gain and retain new customers, create loyalty, generate reliable revenue streams, and manage subscriptions with confidence.
For more information about the Xsolla Web Shop, visit: https://xsolla.com/solution/web-shop-for-mobile-games
NFT Checkout
Xsolla has created an NFT Checkout process to allow developers to quickly and securely add NFTs to their game economy. This feature enables players to make purchases using their preferred payment method. The developer handles the minting and the delivery of the NFTs, while Xsolla handles the checkout and in-game items distribution process.
For more details about NFT Checkout, visit: https://xsolla.com/solution/payments/nft-checkout
Digital Distribution Hub
Xsolla Digital Distribution Hub connects games to a global network of apps, internet service providers (ISPs), banks, and other channels to help developers reach players and gain revenue from every transaction. This new solution empowers gamers to discover and support their favorite games through an optimized multi-platform experience and allows them to pay how and when they want.
Developers can now benefit from increased market penetration and brand awareness through distribution channels, such as super apps, online banking apps and mobile carrier marketplaces. With the Digital Distribution Hub your game can reach a vast audience of new users, save on distribution costs, and boost overall revenue and engagement.
To learn more about Digital Distribution Hub, visit: https://xsolla.com/products/digital-distribution-hub
Xsolla will present these solutions and more at several upcoming events, including GamesBeat Summit 2022, Pocket Gamer Connects Seattle, Nordic Game Show, Pocket Gamer Toronto, China Joy, and gamescom, in the next six months. Register to meet up with the experts at Xsolla by visiting: https://xsolla.com/events .
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the video game industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in Berlin, Seoul, and cities around the world, Xsolla supports major gaming titles like Valve, Twitch, Roblox, Ubisoft, Epic Games, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more.
For additional information and to learn more, please visit: xsolla.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220428005554/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom